New drug cocktail aims to wipe out breast cancer before surgery

NCT ID NCT04877821

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 2 trial tested a combination of sintilimab (an immunotherapy), anlotinib (a drug that blocks blood vessel growth), and standard chemotherapy in 29 people with early-stage triple-negative breast cancer. The treatment was given before surgery to shrink or eliminate the tumor. The main goal was to see how many patients had no cancer left at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sintilimab (immunotherapy), anlotinib (anti-angiogenesis drug), nab-paclitaxel, and carboplatin (chemotherapy)
What this could lead to
If successful, this combination could become a new pre-surgery treatment option for early triple-negative breast cancer, potentially improving the chance of eliminating all cancer before surgery.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to all patients. The combination also carries risks of side effects from immunotherapy, anti-angiogenesis drugs, and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NeoSACT

    Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.